Predicting treatment failure in patients with community acquired pneumonia: a case-control study
- PMID: 24996572
- PMCID: PMC4099489
- DOI: 10.1186/1465-9921-15-75
Predicting treatment failure in patients with community acquired pneumonia: a case-control study
Abstract
Introduction: Treatment failure in community-acquired-pneumonia (CAP) patients is associated with a high mortality rate, and therefore are a matter of great concern in clinical management. Those patients have increased mortality and are a target population for randomized clinical trials.
Methods: A case-control study was performed in patients with CAP (non-failure cases vs. failure cases, discriminating by late and early failure). CRP, PCT, interleukin 1, 6, 8 and 10 and TNF were determined at days 1 and 3 of hospitalization.
Results: A total of 253 patients were included in this study where 83 patients presented treatment failure. Of these, 40 (48.2%) had early failure. A discriminative effect was found for a higher CURB-65 score among late failure patients (p = 0.004). A significant increase on day 1 of hospitalization in CRP (p < 0.001), PCT (p = 0.004), IL-6 (p < 0.001) and IL-8 (p = 0.02), and a decrease in IL-1 (p = 0.06) in patients with failure was observed compared with patients without failure. On day 3, only the increase in CRP (p < 0.001), PCT (p = 0.007) and IL-6 (p < 0.001) remained significant. Independent predictors for early failure were higher IL-6 levels on day 1 (OR = 1.78, IC = 1.2-2.6) and pleural effusion (OR = 2.25, IC = 1.0-5.3), and for late failure, higher PCT levels on day 3 (OR = 1.60, IC = 1.0-2.5), CURB-65 score ≥ 3 (OR = 1.43, IC = 1.0-2.0), and multilobar involvement (OR = 4.50, IC = 2.1-9.9).
Conclusions: There was a good correlation of IL-6 levels and CAP failure and IL-6 & PCT with late CAP failure. Pleural effusion and multilobar involvement were simple clinical predictors of early and late failure, respectively.
Trial registration: IRB Register: http://2009/5451.
Figures




Similar articles
-
Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.Respirology. 2016 Nov;21(8):1459-1464. doi: 10.1111/resp.12846. Epub 2016 Jul 11. Respirology. 2016. PMID: 27398948
-
The diagnostic value of serum procalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosis.Eur Rev Med Pharmacol Sci. 2013 Dec;17(24):3329-33. Eur Rev Med Pharmacol Sci. 2013. PMID: 24379064
-
The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia.Respir Res. 2018 Oct 1;19(1):193. doi: 10.1186/s12931-018-0877-x. Respir Res. 2018. PMID: 30285748 Free PMC article.
-
Biomarkers and community-acquired pneumonia: tailoring management with biological data.Semin Respir Crit Care Med. 2012 Jun;33(3):266-71. doi: 10.1055/s-0032-1315638. Epub 2012 Jun 20. Semin Respir Crit Care Med. 2012. PMID: 22718212 Review.
-
Community-acquired pneumonia: updates in assessment and management.Crit Care Nurs Q. 2004 Jul-Sep;27(3):231-40. doi: 10.1097/00002727-200407000-00004. Crit Care Nurs Q. 2004. PMID: 15291049 Review.
Cited by
-
Predictive Value of Lysophosphatidylcholine for Determining the Disease Severity and Prognosis of Elderly Patients with Community-Acquired Pneumonia.Clin Interv Aging. 2024 Mar 19;19:517-527. doi: 10.2147/CIA.S454239. eCollection 2024. Clin Interv Aging. 2024. PMID: 38528884 Free PMC article.
-
Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients.BMC Infect Dis. 2020 Sep 12;20(1):668. doi: 10.1186/s12879-020-05362-3. BMC Infect Dis. 2020. PMID: 32919458 Free PMC article.
-
Role of Inflammatory Markers as a Risk Factor for Community-Acquired Pneumonia Management.Medicina (Kaunas). 2025 Jun 11;61(6):1078. doi: 10.3390/medicina61061078. Medicina (Kaunas). 2025. PMID: 40572766 Free PMC article.
-
Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.Hum Vaccin Immunother. 2021 Oct 3;17(10):3670-3686. doi: 10.1080/21645515.2021.1923348. Epub 2021 Jun 9. Hum Vaccin Immunother. 2021. PMID: 34106040 Free PMC article.
-
Common Laboratory Parameters for Differentiating Between Community-Acquired and Healthcare-Associated Pneumonia.J Clin Lab Anal. 2017 Jan;31(1):e22016. doi: 10.1002/jcla.22016. Epub 2016 Jun 27. J Clin Lab Anal. 2017. PMID: 27346336 Free PMC article.
References
-
- Garcia-Vidal C, Carratalà J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med. 2009;30:154–60. - PubMed
-
- Ramírez P, Ferrer M, Martí V, Reyes S, Martínez R, Menéndez R, Ewig S, Torres A. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011;39:2211–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous